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Objective: To reach consensus on the core domains to be included in a core domain set for 
clinical trials of shoulder disorders using the Outcome Measures in Rheumatology (OMERACT) 
Filter 2.1 Core Domain Set process.  
Methods: At OMERACT 2018, the OMERACT Shoulder Working Group conducted a workshop 
that presented the OMERACT 2016 preliminary core domain set and its rationale based upon 
a systematic review of domains measured in shoulder trials and an international Delphi 
involving patients, clinicians and researchers, as well as a new systematic review of qualitative 
studies on the experiences of people with shoulder disorders. After discussions in break-out 
groups, the OMERACT core domain set for clinical trials of shoulder disorders was presented 
for endorsement by OMERACT 2018 participants.  
Results: The qualitative review (N=8) identified all domains included in the preliminary core 
set. An additional domain, cognitive dysfunction was also identified but confidence that this 
represents a core domain was very low. The core domain set that was endorsed by the 
OMERACT participants, with 71% agreement, includes four ‘mandatory’ trial domains: pain, 
function, patient global and adverse events including death; and four ‘important but optional’ 
domains: participation (recreation/work), sleep, emotional wellbeing and condition-specific 
pathophysiological manifestations. Cognitive dysfunction was voted out of the core domain 
set.   
Conclusion: OMERACT 2018 delegates endorsed a core domain set for clinical trials of 
shoulder disorders. The next step includes identification of a core outcome measurement set 
that passes the OMERACT 2.1 Filter for measuring each domain.  
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INTRODUCTION 
Shoulder disorders, including rotator cuff disease (tendinopathy, impingement, subacromial 
bursitis, tears), adhesive capsulitis, instability, glenohumeral osteoarthritis, dislocation, 
proximal humeral or humeral head fractures, and unspecified shoulder pain, are highly 
prevalent disorders (7-26%),(1) and are associated with significant morbidity, disability and 
economic burden.(2-4) Despite increasing numbers of trials investigating the benefits and 
harms of treatments for these disorders, there is as yet no widely endorsed core domain set 
(for outcome domains) or core outcome measurement set (for instruments) that is advocated 
for clinical trials.  
The Outcome Measures in Rheumatology (OMERACT) Shoulder Working Group was 
established in 2015 to develop these sets for clinical trials of shoulder disorders.(5) Over the 
past three years, the Working Group has worked on several steps of this project in accordance 
with OMERACT methodology.(6, 7) This has included, firstly, a systematic literature review 
identified that across 409 trials, 32 outcome domains were assessed using 319 different 
measurement instruments.(8) Second, an international Delphi study that included 268 
clinicians or researchers from 13 countries with experience in shoulder disorders and 67 
patients with shoulder disorders.(9) This was followed by a pre-OMERACT meeting (including 
patient representatives) and subsequent Special Interest Group meeting at OMERACT 2016, 
in which a preliminary core domain set was presented and unanimously approved. In Table 1 
the preliminary core domain set as well as the voting percentages of each of them from the 
Delphi are summarized.(10)  
This preliminary core domain set consisted of four domains in the ‘inner circle’ of the 
OMERACT ‘onion’ (indicating mandatory domains for all trials of shoulder disorders): pain, 
physical function/activity, global perceived effect, and adverse events including death; three 
domains in the ‘middle circle’ (important but optional domains): emotional well-being, sleep 
and participation (recreation and work); and a research agenda required to inform the final 
core domain set in the ‘outer circle’. The research agenda was comprised of clarifying the 
definition of physical function/activity, determining whether or not participation (recreation 
and work) should be in the inner circle, and determining whether to include 
pathophysiological manifestations in the core domain set and if it should be situated in the 
inner (mandatory) or middle (important but optional) circle. In the meantime, OMERACT 
nomenclature has been slightly updated as indicated later in the final core domain set. 
Following the abovementioned initiatives, the Working Group proposed a Workshop for 
OMERACT 2018. In preparation for it, the Working Group performed a systematic review of 
qualitative studies that had explored the lived experience of shoulder pain. The purpose of 
this review was to determine whether any potentially relevant domains were missing from 
the preliminary core domain set and to further inform the research agenda.(11) The present 
paper summarizes the results of this work presented at the OMERACT 2018 Shoulder Core 
Set Workshop, the domains that were presented for endorsement, and the results of the 
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plenary and breakout discussions, and subsequent vote for endorsement of the core domain 
set for clinical trials of shoulder disorders. 
 
MATERIALS AND METHODS 
Review of qualitative studies 
To ensure that all important patient outcome domains had been considered, we performed 
a systematic review of qualitative studies that had explored the experiences of people with a 
shoulder disorder.  
The methods for our systematic review were pre-specified (PROSPERO ID: CRD42017082628) 
and the full findings are presented elsewhere.(11) Briefly, we searched for eligible studies 
indexed in Ovid MEDLINE, Ovid Embase, CINAHL (EBSCO), SportDiscus (EBSCO) and Ovid 
PsycINFO to November 2017. Studies in which the authors used qualitative methods (e.g. 
focus groups, Delphi methods, nominal group techniques, participant observation, 
interviews) to explore the experiences and perceptions of people living with a shoulder 
disorder were included.  
The primary outcomes of interest for this review included the symptoms of people with 
shoulder disorders and the impact these symptoms have on their daily lives, and the 
outcome(s) of most importance to patients, as elicited by qualitative research methods. Two 
authors independently screened studies for inclusion, appraised their methodological quality 
(using the Critical Appraisal Skills Programme (CASP) checklist for qualitative studies)(12), 
coded text line-by-line to identify outcome domains (i.e. individual symptoms and perceived 
impacts on daily living) reported by participants, and assessed the confidence in each review 
finding (high, moderate, low, very low) using the GRADE-CERQual approach.(13)  
Eight studies met the eligibility criteria and they included 133 participants (49 females and 84 
males). Studies were conducted in the UK (four studies), Canada (two studies), Finland or New 
Zealand (one study each). Participants had diagnoses of rotator cuff disease (three studies), 
adhesive capsulitis (two studies), proximal humeral fracture, shoulder instability or 
unspecified shoulder pain (one study each).  
Seven domains were identified across the eight qualitative studies: (1) pain; (2) physical 
function/activity limitations (difficulties performing activities of daily living such as dressing 
or bathing); (3) participation restriction (work disruption, limited recreation/leisure, and 
limited social interactions); (4) sleep disruption (difficulty falling, and subsequently staying, 
asleep); (5) cognitive dysfunction (poor concentration and memory); (6) emotional distress 
(frustration, anxiety and depression); and (7) pathophysiological manifestations (problems 
related to muscle functions, such as reduced range of motion and loss of muscle strength).  
We mapped the outcome domains arising from our systematic review of qualitative studies 
against the domains included in the preliminary core domain set, to determine whether any 
important domains were missing. Only one domain, which we termed ‘cognitive dysfunction’, 
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referring to the reported experience that shoulder pain was so severe that it prevented the 
participant from being able to concentrate on anything else, had not been identified in our 
previous research.(8-10) Sleep deprivation due to shoulder pain was also reported to affect 
concentration and memory. However, we had very low confidence in these findings, because 
they were raised by only a few participants from only two studies, one of which had several 
methodological limitations. In contrast, we had greater confidence that the other outcome 
domains identified reflected the experiences of many people with shoulder disorders. For all 
the other domains the confidence in the findings was moderate, except for 
pathophysiological findings, for which confidence was also low (Table 1). 
The review findings were discussed in the monthly teleconferences of the core members of 
the working group, in which convenors, fellows, patient representatives and representatives 
from the OMERACT technical advisory committee participated. Prior to OMERACT 2018 the 
final results were presented in a teleconference with all working group members. Members 
discussed potential modifications to the preliminary core domain set based on the findings of 
the review of qualitative studies. We decided to move condition-specific pathophysiological 
manifestations into the middle rather than inner circle, and added the question, “Should 
‘cognitive dysfunction’ be in the Onion?” to the outer circle (research agenda). No other 
modifications were made before the OMERACT 2018 meeting (Table 1). 
 
OMERACT 2018 Shoulder Core Set Workshop and Plenary 
At OMERACT 2018 the Shoulder Core Set Workshop presented the steps that had been taken 
towards arriving at the proposed core domain set for clinical trials of shoulder disorders and 
the details of the domains that had been included. 
A total of 95 participants (11 patients, 84 other stakeholders – including clinicians, other 
health professionals, researchers, regulators) were split into eight break-out sessions to 
facilitate in-depth discussions of the proposed core set. Each group had a facilitator, content 
expert and reporter. All domains of the proposed core domain set were discussed by all break-
out groups. After reconvening, the reporter for each break-out summarized their group 
discussions to all OMERACT 2018 participants and this was followed by general discussion. 
The Shoulder Working Group collected detailed feedback from each breakout group for 
making further decisions regarding the naming and positioning of domains in the core domain 
set. In a final plenary session on the following day, a revised proposal of a core domain set 
was presented for final discussion and endorsement. To obtain endorsement 70% of the votes 
in favor of the proposed core set were required. Alternatively, revisions were discussed, 
proposed and then re-voted on.  
 
RESULTS 
Break-out group discussions regarding each proposed domain and their definition 
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Pain: There was uniform agreement that pain, reflecting pain intensity, should be included as 
a mandatory domain within the inner circle.  
Function: Function was also recognized as a mandatory domain. It was commented that 
function should not only reflect the ability to fulfil basic needs, so the definition was adjusted 
to reflect normal activities of daily living (see Table 3).  
Adverse events including death: This was also considered to be a mandatory domain 
reflecting OMERACT principles.(6)  
Global perceived effect: This domain elicited the most discussion. There were some concerns 
raised about whether this domain was redundant in view of overlap with the domains of pain 
and function. However, the results of the Delphi study were considered to justify its inclusion 
as a separate domain. Several participants raised the concern that as worded, this domain 
would include a change measure (for example, in relation to some treatment) while their 
preference was for a status measure (i.e., the patients’ perception of their current state). 
Others argued that having a change measure in the core domain set could have a desirable 
effect as it could act as an anchor for other measures when analyzing outcomes in relation to 
each other. Following discussion, consensus was reached to change the name of this domain 
to ‘patient global’. Whether or not this should be measured using a status or change measure 
will be reconsidered in the next phase of identifying suitable measures for this outcome.  
Participation: There were proposals to adjust the definition of participation to ensure that it 
covers both paid and unpaid types of work, and to align the definition of participation to the 
International Classification of Functioning definition.(14) Both of these changes were 
adopted. 
Emotional wellbeing: This domain was identified as having some overlap with the domains of 
patient global and function. However, given the results from the Delphi and the qualitative 
review, no changes to the domain were proposed.  
Condition-specific pathophysiological manifestations: There were a range of divergent 
opinions regarding this domain and where it fits within the OMERACT core domain set for 
shoulder disorders. Arguments for inclusion of this domain within the inner circle focused on 
the fact that this was consistent with OMERACT rules for including at least one domain 
reflecting pathophysiologic manifestations in the inner circle. On the other hand, while 
pathophysiologic manifestations may be relevant for some trials, for example determination 
of fracture healing in a trial investigating treatment for proximal humeral fractures, it may not 
be of value to have a pathophysiologic manifestation included as a core outcome in all trials. 
In addition, there were also arguments for including this domain in the outer circle to reflect 
that more research was needed before this could resolved. For the purpose of voting, this 
domain was kept in the middle circle.  
Sleep: Some discussion surrounded the idea that there are differing constructs that could be 
included within a sleep domain such as sleep quality and the interference/impact of sleep 
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disturbance. However, there were no consistently recommended changes to the definition or 
position of sleep in the core domain set.  
Cognitive dysfunction: This domain was considered to possibly overlap with other domains, 
such as sleep (i.e. lack thereof) or emotional wellbeing (e.g. depression can affect cognition). 
Some expressed it could be kept in the outer circle, while others recommended leaving it out 
of the core domain set altogether. 
 
Results of the final vote  
Seventy-one percent of OMERACT participants approved the inner core domains comprising 
pain, function, patient global and adverse events including death (Table 2). When considered 
individually pain was endorsed by 100% of participants, function by 99% and patient global 
by 80%. No vote was conducted for adverse events (including death) as this is a mandatory 
OMERACT domain.  
For the middle circle, 89% of participants endorsed inclusion of participation, 93% endorsed 
sleep and 82% endorsed emotional wellbeing. Inclusion of condition-specific 
pathophysiological manifestations in the middle circle was only endorsed by 44% of 
participants. There was a spread in the preference of where to allocate condition-specific 
pathophysiologic manifestations, with a preference shown though for the middle circle.  
Cognitive dysfunction was endorsed initially by 64% participants for remaining in the outer 
circle for further research. After further discussion which reminded participants of the results 
of the qualitative review, which had identified poor concentration and memory as relevant to 
the experience of people with shoulder pain, but that there was very low confidence that this 
cognitive dysfunction was truly a main issue, a second vote was conducted and 64% of 
participants endorsed removal of this domain from the core domain set altogether.  
Following OMERACT 2018, an updated OMERACT Onion was approved and implemented. This 
retains the three circles of the onion comprising ‘mandatory’ domains (inner circle), including 
the domain adverse events including death; ‘important but optional’ domains (i.e., 
dependent on the design of the study or research question asked, middle circle); and 
‘research agenda’ (domains of interest that need more research work but are under 
consideration, outer circle). The final core domain set for clinical trials of shoulder disorders 




We have outlined the final steps taken to reach OMERACT endorsement for a core domain 
set for clinical trials of shoulder disorders. This represents a major step forward in 
harmonization of outcome measurement in this field of research. The core domain set 
comprises four ‘mandatory’ domains within the ‘mandatory for all clinical trials’ category: 
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pain, function, patient global and adverse events including death; and four ‘important but 
optional’ domains: participation (recreation/work), sleep, emotional wellbeing and condition-
specific pathophysiological manifestations. Currently there are no items in the new 
‘mandatory in certain circumstances category’ in the inner circle. There were no items 
remaining in the research agenda.  
The next step will be to define a core outcome measurement set, which is a core set of 
instruments that should be used to measure each of the domains. The Working Group is 
already working towards determining which instruments pass the OMERACT 2.0 Truth, 
Discrimination and Feasibility filter. Results of this work will be presented at a future 
OMERACT conference to enable endorsement of specific measures for each domain to be 
included in the final core outcome measurement set and any priorities for future research.  
After reaching widespread agreement of these core domain and outcome measurement sets 
via the OMERACT process, it will be important to implement them. While we work towards 
identifying which measurement instruments pass the OMERACT 2.1 Truth, Discrimination and 
Feasibility filter, researchers designing and conducting trials, observational studies and 
systematic reviews should already consider inclusion of the core domain set as a minimum. 
We will disseminate the OMERACT-endorsed core domain set in workshops at relevant 
meetings as well as use other methods for reaching relevant stakeholder groups (e.g. 
patients, trialists, researchers, clinicians, regulators). We will also ensure a web presence (e.g. 
OMERACT website, links from other sites). In the future, we will also measure the success of 
our implementation strategies by monitoring whether the OMERACT-endorsed core domain 
and outcome measurement sets for clinical trials of shoulder disorders are being used in trials, 
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 NA Very low 
NA – not available, i.e. not included in the Delphi or in the qualitative evidence synthesis 
* Moderate for frustration and anxiety and low for depression 
§ Percentage of votes from the Delphi second round agreeing with the inclusion of the 
domain(9) 
± Confidence in each review finding (high, moderate, low, very low) using the GRADE-












Table 2 – Voting Results from the OMERACT 2018 Shoulder Core Set Workshop 
Domain Votes in favour  
n (%)§ 
Inner Circle 67 (71%) 
- Pain 94 (100%) 
- Physical function 94 (99%) 
- Patient Global 75 (80%) 
- Adverse events including death No vote, mandatory domain 
Middle Circle  
- Participation (recreation/work) 82 (89%) 
- Sleep 85 (93%) 
- Emotional wellbeing 75 (82%) 
- Condition-specific pathophysiological manifestations  40 (44%) 
Outer Circle  
- Cognitive dysfunction  58 (64%) -> 41 (36%)* 
§Throughout the voting process, some participants did not vote for specific domains, so the 
total number of participants may vary for the different domains. 
*In the first vote during the Workshop, 64% of the participants agreed with the proposal to 
keep cognitive dysfunction in the outer circle. It was thus unclear where it should be kept or 
removed, and therefore a second vote was conducted during the Plenary (n=115), in which 
only 36% of the participants indicated to keep it in the Core Domain Set. As a consequence, 



























Table 3 – Definition of the domains included in the Core Domain Set for Shoulder Disorders 
Domain  
Pain How much a person’s shoulder hurts, reflecting the overall 
magnitude of the pain experience (i.e., at rest, during and after 
activity, at night) 
Physical function A person’s ability to carry out daily physical activities, ranging from 
self-care (e.g. bathing, combing hair) to more complex activities that 
require a combination of skills (e.g. driving a car) 
Patient global Patient reported disease-related health status 
Adverse effects 
including death 
Any major or minor adverse event that occurs during 
the course of the trial, including any deaths 
Emotional well-
being 
Effect on a person’s emotions, including levels of depression, 
anxiety, or other types of psychological distress. Depression refers 
to negative mood, loss of self-confidence, loss of motivation, and 





A person’s ability to engage in a life situation, in any form of play, 
recreational or leisure activity acts (e.g. sports of any kind or levels), 
and the ability to meet physical and/or psychological demands of 
work 
Sleep Sleep functions such as onset, maintenance, quality, amount of 
sleep, and functions involving the sleep cycle. This domain also 
includes the effect on perceptions of alertness and sleepiness 
during usual waking hours 
Pathophysiological 
manifestations 
Could be range of motion, muscle strength, radiographic outcomes, 













Figure 1 – Core Domain Set for Shoulder Disorders 
Shoulder disorders include rotator cuff disease (tendinopathy, impingement, subacromial 
bursitis, tears), adhesive capsulitis, instability, glenohumeral osteoarthritis, dislocation, 
proximal humeral or humeral head fractures and unspecified shoulder pain. 
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Statement of Contribution  
 
In the current manuscript we have summarized all the preparatory work from the OMERACT 
Shoulder Working Group that has led to the presentation at a dedicated workshop at 
OMERACT 2018 of the proposed core domain set. This means summarizing the results of 
previously published studies, which consisted of a systematic review of domains measured in 
shoulder trials, an international Delphi involving patients, clinicians and researchers and a 
summary of the OMERACT 2016 Special Interest Group resulting in a preliminary core domain 
set. In the currently submitted manuscript the results of new systematic review of qualitative 
studies on the experiences of people with shoulder disorders were for the first time 
described. Furthermore, the discussions taking place at the Shoulder Workshop at OMERACT 
2018, as well as the voting results are presented. In summary, the qualitative review (N=8) 
identified all domains included in the preliminary core set. An additional domain, cognitive 
dysfunction was also identified but confidence that this represents a core domain was very 
low. The core domain set that was endorsed by the OMERACT 2018 participants, with 71% 
agreement, includes four ‘mandatory’ trial domains: pain, function, patient global and 
adverse events including death; and four ‘important but optional’ domains: participation 
(recreation/work), sleep, emotional wellbeing and condition-specific pathophysiological 
manifestations. Cognitive dysfunction was voted out of the core domain set.  OMERACT 2018 
delegates endorsed a core domain set for clinical trials of shoulder disorders and this 
represents a major step forward in harmonization of outcome measurement in this field. The 
currently submitted manuscript has not been submitted elsewhere and includes only new 
data, clearly advancing the field of shoulder disorders and outcome measurement. 
 
 
